No. | Cancer type | Molecular alteration | Matched therapy | Response | Progression free survival (month) |
---|---|---|---|---|---|
1 | Bile duct | FGFR2 | FGFR inhibitor | PD | 0.95 |
2 | Cervical | PIK3CA E542K | PI3K inhibitor | NE | 2.53 |
3 | Liver | TSC1 | mTOR inhibitor | NE | 0.82 |
4 | Breast | BRCA1 | PARP inhibitor | PR | 8.09 |
5 | Peritoneal | BRCA1 | PARP inhibitor | SD | 7.17 |
6 | Cervical | PIK3CA E542K | AKT inhibitor | PD | 0.72 |
7 | Breast | PIK3CA H1047R | PI3K inhibitor | PR | 6.18 |
8 | Breast | PIK3CA E545K | PI3K inhibitor | SD | 2.80 |
9 | Breast | PIK3CA E545V | PI3K inhibitor | SD | 5.72 |
10 | Breast | AKT1 E17K | AKT inhibitor | PR | 14.1 |
11 | Breast | BRCA1 | PARP inhibitor | SD | 5.53 |